PTGS2 and Alzheimer disease: Further, a six-month, double-blind, placebo-controlled study revealed that the non-selective COX inhibitor indomethacin (seven times more effective for COX-1 than COX-2) appeared to protect mild to moderately impaired Alzheimer’s disease patients from the degree of cognitive decline as compared to a placebo-treated group [38].